Uncategorized

Pfizer Reports More Exubera Problems

Pfizer (NYSE:PFE) is the latest company to report third quarter results. According to the press released issued by the company “Exubera’s innovative and complex manufacturing process requires highly automated, specially engineered Pfizer equipment. As in any large-scale manufacturing process utilizing advanced technology, we have experienced typical scale-up issues that we have made significant progress in addressing. Over the next few months, we will continue our ramp-up of Exubera to provide...

Amylin Reports

This afternoon Amylin (NASDAQ:AMLN) reported solid third quarter results. The company reported total revenue of $147 million for the quarter; these results included sales of $126.4 million for Byetta® and $12.4 for Symlin®. The company also increased their full year guidance for Byetta and Symlin sales from $475 million to over $500 million. As expected during the Q&A portion of the call questions centered on the approval of Januvia...

Game on continued- Januvia receives FDA approval

This morning Merck (NYSE:MRK) announced the Food and Drug Administration has granted approval for Januvia™ an oral medication for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. JANUVIA belongs...

JNJ and Roche Report

This morning Johnson and Johnson (NYSE:JNJ) and Roche reported third quarter results. Currently JNJ’s Lifescan unit and Roche’s Accu-Chek unit are fighting for market share in the increasingly competitive blood glucose monitoring market. Depending on which set of numbers you want to believe Roche is currently number one worldwide with Lifescan a close second. Number three in the category is Abbott (NYSE:ABT) who reports results on Wednesday morning. Based...

Game On

This morning Reuters announced results of a survey on two new oral medications for the treatment of type 2 diabetes. Januvia from Merck (NYSE:MRK) and Galvus from Novartis (NYSE:NVS) are both awaiting Food and Drug Administration (FDA) approval. Both drugs are DPP-4 inhibitors and in clinical trials have shown solid results. Both drugs have the potential to reach blockbuster status mainly due to the lack of adverse side effects. ...

Non-invasive glucose monitoring a realistic assessment

It’s not often that a company involved in the quest to develop a non-invasive glucose monitor gives up. This is a space where the motto is “If at first you don’t succeed, go out and raise more money and keep trying.” Although no one has been successful in bringing a truly non-invasive glucose monitor to market and the list of those who have tried and failed is long and distinguished,...

The return of non-invasive glucose monitoring

This morning NIR Diagnostics (TSX Venture: NID) announced that they have reached an agreement with Lifescan, a unit of Johnson and Johnson (NYSE:JNJ), to extend by six months a feasibility study and first option agreement previously announced on January 3, 2006. NIR is seeking to develop a non-invasive glucose monitor. What’s interesting about this announcement is the wording of the January announcement. Back in January NIR’s press release stated,...

The return of non-invasive glucose monitoring

This morning NIR Diagnostics (TSX Venture: NID) announced that they have reached an agreement with Lifescan, a unit of Johnson and Johnson (NYSE:JNJ), to extend by six months a feasibility study and first option agreement previously announced on January 3, 2006. NIR is seeking to develop a non-invasive glucose monitor. What’s interesting about this announcement is the wording of the January announcement. Back in January NIR’s press release stated,...

Finally Roche Back in the US insulin pump market

This morning Roche announced that the US Food and Drug Administration (FDA) has lifted the import alert for the sale of Accu-Chek insulin pumps by Disetronic Medical Systems AG (Burgdorf, Switzerland) for customers in the United States. Roche’s re-entry into the US insulin pump market comes at a difficult time. At one time Disetronic was a firm number two behind market leader Medtronic (NYSE:MDT). While Medtronic maintains their market dominance,...

Amylin -Are the shorts at it yet again?

Back in August while attending the American Association of Diabetes Educators (AADE) Conference in Los Angeles. Diabetic Investor heard rumors surrounding a possible link between Byetta and pancreatitis. Although we had not heard of any major problems with Byetta, Diabetic Investor investigated the issue and didn’t find any cause for concern. Seeing no need to write anything on what we believed was an effort by the short community to...